No

Corticosteroid, Topical

Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid)

C

Hypersensitivity to prednicarbate or any component; fungal, viral, or tubercular skin lesions, herpes simplex or zoster

Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression. This is more likely to occur when the preparation is used on large surface or denuded areas for prolonged periods of time or with an occlusive dressing.

1% to 10%: Dermatologic: Skin atrophy, shininess, thinness, mild telangiectasia

<1%: Pruritus, edema, urticaria, burning, allergic contact dermatitis and rash, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, striae, miliaria, paresthesia

No data reported

Topical corticosteroids have anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative actions

Adults: Topical: Apply a thin film to affected area twice daily. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.

Relief of symptoms

None reported

None reported

No information available to require special precautions

No effects or complications reported

Use only as prescribed and for no longer than the period prescribed; apply sparingly in a thin film and rub in lightly; avoid contact with eyes; do not apply to the face, underarms, or groin areas; notify physician if condition persists or worsens

Use sparingly

Cream: 0.1% (15 g, 60 g)

Rumbaugh MM, "High Potency Topical Corticosteroids," US Pharm, 1993, 18(6):30-41.